Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri Tbk's EBIT per Share for the
three
months ended in Mar. 2026 was Rp4.90.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was Rp18.75.
During the past 12 months, the average EBIT per Share Growth Rate of PT Jayamas Medica Industri Tbk was 26.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 1.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -16.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PT Jayamas Medica Industri Tbk's EBIT per Share or its related term are showing as below:
ISX:OMED'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.3 Med: -10.3 Max: 8.4
Current: 1.6
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of PT Jayamas Medica Industri Tbk was 8.40% per year. The lowest was -29.30% per year. And the median was -10.30% per year.
ISX:OMED's 3-Year EBIT Growth Rate is ranked worse than 61.46% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs ISX:OMED: 1.60
PT Jayamas Medica Industri Tbk (ISX:OMED) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PT Jayamas Medica Industri Tbk EBIT per Share Related Terms
PT Jayamas Medica Industri Tbk EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp18.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a EBIT per Share of Rp18.75 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Jayamas Medica Industri Tbk and its competitors. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #421 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 61.5%.
Is PT Jayamas Medica Industri Tbk's EBIT per Share too high?
PT Jayamas Medica Industri Tbk's current EBIT per Share is Rp18.75. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #421 out of 685 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #421 out of 685 companies for EBIT per Share. This places PT Jayamas Medica Industri Tbk in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Jayamas Medica Industri Tbk and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current EBIT per Share is Rp18.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp238.52, compared to a current price of Rp208.00 — trading 12.8% below its estimated fair value. The current EBIT per Share is Rp18.75. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current EBIT per Share is Rp18.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp208.00 is trading 12.8% below its estimated GF Value™ of Rp238.52.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Modestly Undervalued.
Key valuation signals for ISX:OMED:
EBIT per Share: Rp18.75
GF Value™: Rp238.52 vs. price of Rp208.00 (12.8% below fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk Business Description
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score
Get the complete analysis for ISX:OMED
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
